

# Project Profile: Fareva

## Increasing Vaccine Fill-Finish Capacity in France: 500M Unit Annual Capacity for Single-Dose Prefilled Vaccine Injectables

The supply chain challenges that emerged during the COVID-19 pandemic has shown the importance of both localized manufacturing and the need for flexible scale. That was one of the main drivers behind Fareva, a leading CDMO with facilities across multiple continents, establishing a 10-year licensing agreement with ApiJect in December 2021.

Fareva manufactures and packages a wide range of pharmaceutical products through development, production and packaging of new innovative drugs or existing products, no matter the dosage form. As a multi-generational family-owned business, Fareva has developed a deep knowledge and appreciation for Blow-Fill-Seal (BFS), a rapid and efficient aseptic packaging process used for sterile pharmaceuticals and other liquid products.

Fareva, with support from France Relance – a €100 billion investment initiative into domestic manufacturing by the French government – identified ApiJect's technology to increase Fareva's BFS capabilities and grow Europe's fill-finish for vaccines and other injectables.

### INSTALLATION

Fareva is installing three BFS production lines that, when operational, will be able to fill-finish more than 500 million doses per year of vaccines and other large-molecule injectable drugs using ApiJect's innovative prefilled injector

technology. The new lines will be installed in Fareva Excelvision, located in Annonay, France, which has more than 50 years of experience manufacturing BFS containers and exporting products around the world.

### SCALING UP USING LOCAL SUPPLY CHAINS

As mentioned at the outset, COVID-19 is forcing more pharma companies and CMO/CDMOs to re-evaluate the strength and reliability of their supply chains, with an eye

towards regional manufacturing. BFS is in many ways ideal for this regional manufacturing focus because its supply chain is only reliant upon pharmaceutical-grade resin as a primary material, and ApiJect's combination injector technology only adds one more primary material: cannula for needles.

By investing in these three BFS lines and ApiJect's technology, Fareva is helping to increase Europe's high-speed, high-volume fill and finish capacity by potentially more than 500 million doses per year. Additionally,

clean rooms for these new lines will operate in a BSL2 environment, enabling the handling of most vaccines. Expectations are to start the first validation batches in June 2022.

When cleared by regulators, ApiJect will provide the necessary needle hub and other attachable components to convert finished BFS single-dose containers from these lines into easy-to-assemble, ready-to-use prefilled injectors\*.



\*The Prefilled ApiJect Injector has not been cleared by the FDA or other regulatory bodies.